The Dermatology Digest

DECEMBER 15, 2023

They reviewed the available safety data and analyzed the risk of 11 adverse events from 14 RCTs published between 2019 and 2022. The post Review Study Aims to Refine Safety Profile of JAK Inhibitors in AD appeared first on The Dermatology Digest.

Safety 36

Safety Dermatitis Dermatology Management 36

The Dermatology Digest

FEBRUARY 8, 2024

It has great efficacy and safety and is oral… [This means] no shot and no risk of anaphylaxis.” Upadacitinib’s (Rinvoq, AbbVie) 5-yr safety data show that it is REALLY SAFE and effective in AD, and abrocitinib (Cibinqo, Pfizer) is safe as well.” The BIG story is Janus kinase ( JAK ) inhibitors,” Dr. Martin says.

Dermatology 78

Dermatology Eczema Pharmaceutical Dermatitis 78

The Dermatology Digest

OCTOBER 26, 2024

Atopic dermatitis (AD) patients who switched to upadacitinib (Rinvoq, AbbVie) from dupilumab (Dupixent, Regeneron, and Sanofi) hit higher treatment targets, according to results from Period 2 of the LEVEL UP study. achieved an Eczema Area and Severity Index (EASI) of 75, 90, and 100, respectively. In the switchers, 47.6%

Dermatitis 36

Dermatitis Treatments Pharmaceutical Eczema 36

The Dermatology Digest

FEBRUARY 14, 2024

Food and Drug Administration (FDA) has accepted Galderma’s Biologics License Applications for nemolizumab for the treatment of patients with prurigo nodularis (PN) and for adolescents and adults with moderate to severe atopic dermatitis (AD). Galderma is planning for multiple regulatory submissions in 2024.

Dermatitis 78

Dermatitis Clinic Safety Dermatology 78

The Dermatology Digest

SEPTEMBER 25, 2024

Upadacitinib (Rinvoq, AbbVie) performed well in moderate-to-severe atopic dermatitis (AD) patients with head and neck involvement, according to a new post-hoc analysis from the Measure Up 1 and Measure Up 2 Phase 3 studies. 307) 67.8 (320) 320) 75.9 (323) 323) 4 to 7.2 severe) 10.5 (152) 152) 47.2 (142) 142) 63.2 (136) 304) 22.3 (319)

Dermatitis 36

Dermatitis Dermatology Eczema Safety 36

The Dermatology Digest

FEBRUARY 14, 2024

and is the same strength and formulation studied in the ADORING Phase 3 development program and included in the sNDA submission for atopic dermatitis. VTAMA cream, 1% data indicated no new safety or tolerability signals of concern in this population including children 2 years of age and older.

Dermatitis 74

Dermatitis Office Management Eczema 74

The Dermatology Digest

JANUARY 16, 2024

and Sanofi), adding efficacy and safety data for people aged 12 years and older with atopic dermatitis (AD) and uncontrolled moderate-to-severe hand and/or foot involvement. “It is important to have systemic treatments approved for CHE, both with and without atopic dermatitis. and Sanofi report. “We

Dermatitis 36

Dermatitis Pharmaceutical Safety Dermatology 36

The Dermatology Digest

DECEMBER 15, 2023

Food and Drug Administration (FDA) has expanded the approval of tralokinumab-ldrm (Adbry, LEO Pharma Inc) to include kids aged 12-17 years with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

Dermatitis 28

Dermatitis Eczema Safety Therapy 28

The Dermatology Digest

JANUARY 11, 2024

of atopic dermatitis (AD) patients using Vtama (tapinarof) cream, 1% achieved Eczema Area and Severity Index (EASI )75 in an integrated analysis of all the ADORING Program studies, Dermavant reports. No new safety signals were observed with long-term use. Fully 80.7%

Dermatitis 36

Dermatitis Safety Eczema Sensitive Skin 36

The Dermatology Digest

JANUARY 14, 2024

The overwhelming majority of people with atopic dermatitis (AD) treated with investigational roflumilast cream 0.15% (Zoryve, Arcutis) showed a measurable improvement in Eczema Area and Severity Index (EASI) in 4 weeks, according to new pooled analyses from two Phase 3 studies. Fully 91.5%

Dermatitis 36

Dermatitis Safety Dermatology Hospital 36

The Dermatology Digest

MARCH 10, 2024

More than two-thirds of people with atopic dermatitis (AD) and darker skin tones treated with lebrikizumab showed improvements in skin clearance and itch relief, according to late-breaking results from a Phase 3 study are being presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting in San Diego.

Skin Types 36

Skin Types Fitzpatrick Scale Dermatitis Safety 36

The Dermatology Digest

JANUARY 23, 2024

Nemolizumab improves skin lesions, itch, and sleep disturbance in patients with moderate-to-severe atopic dermatitis (AD), according to results from two phase 3 studies. Galderma’s nemolizumab is a first-in-class interleukin-31 receptor alpha antagonist that is under investigation for atopic dermatitis.

Dermatitis 36

Dermatitis Safety Sustainability Eczema 36

The Dermatology Digest

DECEMBER 19, 2023

Aldeyra Therapeutics’ investigational RASP modulator ADX-629 performed well in a Phase 2 clinical trial of patients with atopic dermatitis (AD), according to topline results. The primary endpoint of the clinical trial was safety and tolerability. There were no observed serious adverse events or discontinuations due to adverse events.

Dermatitis 36

Dermatitis Eczema Clinic Therapy 36

The Dermatology Digest

JANUARY 30, 2024

Five investigators have received funding through the 2023 PeDRA Research Grants, Career Bridge Research Grant, Pediatric Alopecia Areata Challenge Grant, and Childhood Eczema Challenge Grant programs. The post And the Winners Are…PeDRA Announces 2023 Grant Recipients appeared first on The Dermatology Digest.

Partnerships 36

Partnerships Eczema Hospital Dermatology 36

The Dermatology Digest

MARCH 7, 2024

Alphyn’s zabalafin hydrogel (AB-101a) performed well in patients with atopic dermatitis (AD), including disease commonly associated with Staphylococcus aureus and methicillin-resistant Staph , according to new Phase 2a data.

Safety 36

Safety Dermatitis Eczema Clinic 36

The Dermatology Digest

MAY 16, 2024

This grant will fund a collaborative effort to investigate the safety, tolerability, efficacy, and durability of response of subcutaneous administration of dupilumab in pediatric patients with extensive alopecia areata, defined as affecting at least 30% of the scalp.

Eczema 69

Eczema Dermatitis Safety Innovations 69

The Dermatology Digest

MARCH 11, 2024

In addition, results from the phase III ARCADIA clinical trials in atopic dermatitis (AD) found that nemolizumab-treated patients who responded at 16 weeks maintained skin and itch responses through to week 48, even when dosing was reduced from every four to every eight weeks. No new safety signals were observed in this trial.

Dermatitis 36

Dermatitis Safety Dermatology Eczema 36

First Derm

DECEMBER 26, 2023

Dandruff (Seborrheic Dermatitis) Dandruff, medically known as seborrheic dermatitis , is a common scalp condition marked by excessive shedding of skin cells. Skin Conditions (Eczema, Psoriasis, Contact Dermatitis) as Causes of Dry, Itchy Scalp Various skin conditions can lead to a dry, itchy scalp: a.

Management 64

Management Dermatitis Eczema Consultations 64

The Dermatology Digest

APRIL 22, 2024

Adult atopic dermatitis (AD) patients previously treated with dupilumab (Dupixent, Regeneron and Sanofi) who received 400mg eblasakimab weekly achieved Eczema Area Severity Index (EASI) 90, and 66.7% Treatment was well-tolerated and no new safety signals were identified.

Pharmaceutical 36

Pharmaceutical Dermatitis Eczema Injections 36

The Dermatology Digest

MARCH 11, 2024

Sanofi’s investigational OX40-ligand blocker amlitelimab produces sustained improvement in the signs and symptoms of atopic dermatitis (AD) in adults who previously responded and continued treatment and sustained off-drug improvements in those who stopped treatment. This could offer an important benefit in the treatment of AD patients.”

Sustainability 36

Sustainability Dermatitis Safety Hospital 36

The Dermatology Digest

MAY 6, 2024

The Phase 2a trial ( NCT05984784 ) evaluates the safety, pharmacokinetics, and efficacy of IMG-007 in adult patients with moderate-to-severe AD who had inadequate response to and/or intolerant of topical therapies. Key study endpoints include safety and percent change from baseline in eczema area and severity index (EASI) over time.

Safety 36

Safety Dermatitis Therapy Dermatology 36

The Dermatology Digest

JULY 25, 2024

Galderma’s IL- 31 blocker nemolizumab performed well in the phase III ARCADIA 1 and 2 atopic dermatitis (AD) trials. Moreover, 44% and 42% of nemolizumab-treated patients in ARCADIA 1 and 2 achieved at least a 75% improvement in the eczema area and severity index score, when compared to the placebo group.

Dermatitis 36

Dermatitis Safety Eczema Clinic 36

Aesthetics Advisor

JULY 21, 2024

The Council has urged manufacturers to enhance product safety measures, and advised consumers to exercise caution when selecting and using hair styling products. The Council urged suppliers to improve product labeling for consumer safety. head sores), and if not handled properly will increase the risk of scarring and hair loss.

Waxing 36

Waxing Sensitive Skin Eczema Pores 36

First Derm

FEBRUARY 21, 2024

Social media significantly influences the popularity of retinol among young people, leading to increased experimentation without considering safety. However, there are concerns about the safety of using retinol on younger skin due to the physiological differences between children’s and adults’ skin.

Retinol 104

Retinol Social Media Skincare Routine Skincare 104

The Dermatology Digest

DECEMBER 20, 2023

Tim Raducha-Grace Named Chief Platform Officer at Zerigo Health Tim Raducha-Grace is the new Chief Platform Officer at Zerigo Health, a connected phototherapy platform that couples a handheld Narrow-band ultraviolet B (NB-UVB) light device with a smartphone app and team of care providers to allow patients to treat psoriasis and eczema at home.

Dermatology 36

Dermatology Surgery Eczema Office 36

The Dermatology Digest

DECEMBER 18, 2023

New practice parameters from the Joint Task Force for Practice Parameter) recommend the use of topical corticosteroids or topical calcineurin inhibitors in patients with uncontrolled atopic dermatitis (AD) despite moisturizer use. Suggest the usage of crisaborole 2% ointment for mild to moderate atopic dermatitis. in a news release. “It

Dermatitis 36

Dermatitis Partnerships Therapy Safety 36

The Dermatology Digest

DECEMBER 21, 2023

Janus kinase (JAK) inhibitors are revolutionizing the way certain inflammatory diseases such as atopic dermatitis (AD) are being treated, but a more nuanced approach may be needed in modulating JAK activity for conditions like asthma. This is the main takeaway message from a new study in the December 21, 2023, issue of Cell.

Dermatitis 36

Dermatitis Eczema Safety Dermatology 36

The Dermatology Digest

JANUARY 8, 2024

This study was a 16-week, Phase 2, randomized, double-blind, parallel group, placebo controlled, dose-ranging, multicenter study that evaluated the safety and efficacy of lutikizumab in 153 adult patients with moderate to severe HS who had previously failed anti-TNF therapy. Serious adverse events (SAEs) occurred in 5.3%

Medical 36

Medical Clinic Therapy Eczema 36

Kind of Stephen

AUGUST 3, 2022

Some dermatologists might recommend a patient with eczema to take a 5-to-10-minute bath in very dilute bleach (0.005%). It’s thought to help patients with eczema by reducing the levels of Staphylococcus aureus bacteria on the skin.

Sanitation and Sterilization 52

Sanitation and Sterilization Sanitation Eczema Skincare 52

US Dermatologt Partners

SEPTEMBER 23, 2024

Chronic skin conditions – poorly managed chronic skin conditions like eczema and dermatitis may damage or dilate blood vessels around the eyes. It is imperative to have these treatments performed by a licensed professional well-trained in eye safety. Acne scarring or untreated acne breakouts can cause darkening of skin.

Treatments 41

Treatments Chemical Peels Skincare Routine Sun Protection 41

US Dermatologt Partners

JANUARY 24, 2024

We have several non-steroid topical creams, two oral medications, phototherapy, and for our most severe patients, injections with excellent safety profiles and high success rates.” Today, we have a vast number of treatment options that can help us customize treatment plans for our patients. Reach out to healthcare professionals at U.S.

Management 36

Management Skin Health Medical Dermatology 36

The Dermatology Digest

AUGUST 4, 2023

According to Dr. Richard, today she uses many approaches, including biologics (as monotherapy and in combination), as well as phototherapy, to treat patients with psoriasis, eczema, vitiligo, and a “laundry list” of other skin diseases that respond to light. It has a great [safety and efficacy] profile. It’s a great adjunct therapy.

Eczema 36

Eczema Private Practice Therapy Dermatitis 36